Trial Watch; Feb 2026 Edition 4
February U.S. Clinical Trial Intelligence
February 2026 saw a broad range of clinical‑trial activity across oncology, neurology, infectious disease, rare disorders, and advanced genetic therapies in the United States. While precision oncology and rare‑disease programs continued to dominate early‑phase innovation, this period also highlighted a notable rise in preventive immunology and gene‑editing approaches.
Therapeutic Areas Covered
Oncology and Precision Medicine
4 trialsStenoparib + Temozolomide; Relapsed Small‑Cell Lung Cancer (Phase 2)
Biomarker‑guided combination targeting DNA‑repair and Wnt signaling pathways across VA sites
Timeline / Sites
3 Feb 2026: Allarity Therapeutics announced that enrollment is open across 11 Veterans Affairs sites for a Phase 2 trial combining stenoparib with temozolomide in relapsed small‑cell lung cancer. The biomarker‑guided study represents a novel strategy for a historically difficult‑to‑treat malignancy.
What's New
Enrollment opened across 11 Veterans Affairs sites for a biomarker‑guided combination targeting DNA‑repair and Wnt signaling pathways, representing a novel strategy for a historically difficult‑to‑treat malignancy.
Why It Matters
Small‑cell lung cancer remains one of the most challenging oncology indications. A biomarker‑guided approach could improve patient selection and response rates in this underserved population.
FG001; High‑Grade Glioma (Registration‑Oriented Phase 2)
uPAR‑targeted fluorescent imaging agent designed to improve surgical precision and tumor resection outcomes
Timeline / Sites
20 Feb 2026: FluoGuide announced the initiation of the FG001 Phase 2 trial in high‑grade glioma. The registration‑oriented study evaluates a uPAR‑targeted fluorescent imaging agent designed to improve surgical precision and tumor resection outcomes.
What's New
FluoGuide initiated a registration‑oriented Phase 2 trial evaluating FG001, a uPAR‑targeted fluorescent imaging agent designed to improve surgical precision and tumor resection outcomes in high‑grade glioma.
Why It Matters
Fluorescence‑guided surgery could significantly improve resection completeness in high‑grade glioma, potentially extending progression‑free survival through better surgical outcomes.
MOMENTUM Trial; Cemsidomide + Dexamethasone for Multiple Myeloma (Phase 2)
Targeted protein degrader combined with dexamethasone for relapsed or refractory multiple myeloma
Timeline / Sites
23 Feb 2026: C4 Therapeutics announced dosing of the first patient in the Phase 2 MOMENTUM trial evaluating cemsidomide combined with dexamethasone for relapsed or refractory multiple myeloma. The trial builds on encouraging early data and may introduce a new oral therapy option for heavily pretreated patients.
What's New
C4 Therapeutics dosed the first patient in this open‑label study evaluating the targeted protein degrader cemsidomide combined with dexamethasone for relapsed or refractory multiple myeloma.
Why It Matters
Protein degradation represents a rapidly growing therapeutic modality. Success here could validate oral degrader‑based combination regimens for heavily pretreated myeloma patients.
SOTERIA Basket Trial; Lysosomal Storage Disorders (Phase 2)
PLX‑200 evaluated across four rare pediatric neurodegenerative disorders
Timeline / Sites
Feb 2026: Polaryx Therapeutics selected a CRO for the SOTERIA Phase 2 basket trial evaluating PLX‑200 across four rare pediatric neurodegenerative disorders, illustrating the growing use of basket‑trial designs to accelerate development in ultra‑rare diseases.
What's New
This multi‑indication study will evaluate PLX‑200 across four rare pediatric neurodegenerative disorders, illustrating the growing use of basket‑trial designs to accelerate development in ultra‑rare diseases.
Why It Matters
Basket trials allow simultaneous evaluation across multiple related rare diseases, potentially accelerating regulatory timelines and reducing costs for ultra‑rare disease programs.
Neurology, Cell Therapy and Gene Editing
3 trialsNouvNeu001; Parkinson's Disease (Phase IIa)
Off‑the‑shelf iPSC‑derived dopaminergic progenitor cell therapy to replace lost neurons and restore motor function
Timeline / Sites
Feb 2026: iRegene Therapeutics dosed the first U.S. patient in a Phase IIa study evaluating NouvNeu001, an off‑the‑shelf iPSC‑derived dopaminergic progenitor cell therapy designed to replace lost neurons and restore motor function in Parkinson's disease.
What's New
The first U.S. patient was dosed in a study evaluating an off‑the‑shelf iPSC‑derived dopaminergic progenitor cell therapy designed to replace lost neurons and restore motor function.
Why It Matters
This represents a significant milestone in regenerative medicine for Parkinson's disease, demonstrating that iPSC‑derived cell therapies are moving beyond early safety studies into efficacy evaluation.
TSRA‑196; Alpha‑1 Antitrypsin Deficiency (Phase 1/2)
Gene Writing platform to correct SERPINA1 mutation with a single intravenous dose
Timeline / Sites
23 Feb 2026: Tessera Therapeutics announced initiation of the first‑in‑human study of TSRA‑196 for the treatment of alpha‑1 antitrypsin deficiency, using its Gene Writing platform to correct the SERPINA1 mutation with a single intravenous dose.
What's New
Tessera Therapeutics initiated a first‑in‑human study using its Gene Writing platform to correct the SERPINA1 mutation with a single intravenous dose, marking an important milestone in in‑vivo gene editing.
Why It Matters
This trial represents a major advance in precision gene editing, potentially offering a one‑time curative treatment for a genetic condition that currently requires lifelong management.
XPro1595; Early Alzheimer's Disease (Phase 2b/3)
Integrated program targeting neuroinflammation with regulatory alignment
Timeline / Sites
12 Feb 2026: INmune Bio announced FDA alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer's disease, targeting neuroinflammation and potentially accelerating development of a disease‑modifying therapy.
What's New
An integrated Phase 2b/3 program targeting neuroinflammation received regulatory alignment, potentially accelerating development of a disease‑modifying therapy.
Why It Matters
FDA alignment on an integrated Phase 2b/3 pathway could significantly shorten the timeline to potential approval, representing a new approach to Alzheimer's treatment through neuroinflammation modulation.
Infectious Disease and Preventive Immunology
2 trialsINNA‑051 Intranasal Prophylaxis; Respiratory Viruses (Phase 2)
TLR2/6 agonist nasal spray to boost innate immunity and prevent seasonal respiratory infections
Timeline / Sites
Feb 2026: The University of Maryland School of Medicine launched a large randomized Phase 2 study evaluating INNA‑051, a TLR2/6 agonist nasal spray, to boost innate immunity and prevent seasonal respiratory infections in healthy adults.
What's New
A large randomized study will evaluate whether a TLR2/6 agonist nasal spray can boost innate immunity and prevent seasonal respiratory infections in healthy adults.
Why It Matters
If successful, this innate immune primer could offer a broadly protective, non‑vaccine approach to preventing respiratory infections; a significant public health advancement.
LIBERTY Trial; VYD‑2311 COVID‑19 Prophylaxis (Phase 3)
Monoclonal antibody VYD‑2311 compared with mRNA vaccines for COVID‑19 prevention
Timeline / Sites
3 Feb 2026: Invivyd announced FDA agreement on a Phase 3 clinical trial plan evaluating VYD‑2311 for proactive protection against COVID‑19. The pivotal trial will compare the monoclonal antibody with mRNA vaccines, reflecting growing interest in next‑generation preventive strategies.
What's New
Invivyd reached FDA agreement on a pivotal trial comparing its monoclonal antibody VYD‑2311 with mRNA vaccines, reflecting growing interest in next‑generation preventive strategies.
Why It Matters
A head‑to‑head comparison of monoclonal antibody prophylaxis versus mRNA vaccines could reshape the COVID‑19 prevention landscape, particularly for immunocompromised populations.
Rare Diseases and Metabolic Disorders
2 trialsHERO Trial; ARD‑101 for Prader‑Willi Syndrome (Phase 3)
ARD‑101 therapy targeting appetite regulation pathways with expanded pediatric eligibility
Timeline / Sites
10 Feb 2026: Aardvark Therapeutics announced FDA submission and IRB approval of an amended trial protocol for ARD‑101, expanding eligibility in the Phase 3 HERO trial in Prader‑Willi Syndrome. The protocol expansion lowered the enrollment age to seven years, enabling earlier evaluation.
What's New
Protocol expansion lowered the enrollment age to seven years, enabling earlier evaluation of ARD‑101, a therapy targeting appetite regulation pathways.
Why It Matters
Expanding eligibility to younger children addresses a critical need in Prader‑Willi Syndrome, where earlier intervention could have more meaningful impacts on appetite regulation and quality of life.
DARÉ‑HPV; Persistent HPV Infection (Phase 2)
Topical antiviral gel for persistent high‑risk HPV infection
Timeline / Sites
23 Feb 2026: Daré Bioscience announced FDA clearance of the IND application for DARÉ‑HPV to treat persistent HPV infection, enabling Phase 2 initiation later in 2026.
What's New
FDA clearance was granted for a study evaluating a topical antiviral gel aimed at treating persistent high‑risk HPV infection, an area with significant unmet need.
Why It Matters
Persistent high‑risk HPV infection is the leading cause of cervical cancer. A topical treatment option could provide a non‑invasive alternative for patients who do not clear the virus naturally.
Emerging Trends
Preventive Therapeutics Gain Momentum
From intranasal immune primers to monoclonal antibody prophylaxis, the pipeline increasingly targets disease prevention rather than treatment alone.
Advanced Modalities Continue to Mature
Gene editing and cell‑replacement therapies are transitioning from experimental concepts to early clinical validation across neurology and rare diseases.
Precision Oncology Expands Beyond Targeted Drugs
Protein degraders, biomarker‑driven combinations, and fluorescence‑guided surgery illustrate the widening scope of precision approaches.
Innovative Trial Designs for Rare Diseases
Basket trials and adaptive designs are becoming key tools to accelerate development in small patient populations.
Trial Watch by Kitsa
Clinical‑trial activity in February 2026 reflects a rapidly diversifying innovation landscape. Early‑phase oncology remains a major driver, but the growing presence of preventive immunology, gene editing and regenerative medicine signals a shift toward more transformative therapeutic strategies. As these programs advance, they will shape the next wave of Phase 3 trials and future standards of care across multiple therapeutic areas.
Explore Our Blogs
Keep exploring
Recommended next
- Trial Watch
Trial Watch Newsletter — February Edition 3
February 2026, Edition 3.
- Trial Watch
Trial Watch Newsletter — April Edition 7
April 2026, Edition 7.
- Trial Watch
Trial Watch Newsletter — January Edition 1
January 2026, Edition 1: new trial starts and design-risk callouts.
- Blog
Alzheimer's Trial Watch: October 2025
182 trials, 138 drugs, and the first FDA-cleared blood-based IVD for Alzheimer's diagnosis. What shaped the clinical trial pipeline in 2025.